Vitamin D and cardiovascular disease

Circulation Research

Volumn 114, Issue 2, 2014, Pages 379-393

  Norman, P E ^a   Powell, J T ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

25(OH)2D; Cardiovascular disease; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN;

ATHEROSCLEROSIS; AUTOCRINE EFFECT; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CELL FUNCTION; CLINICAL STUDY; DISEASE ASSOCIATION; ENDOCRINE SYSTEM; ENDOTHELIUM CELL; EXPERIMENTAL STUDY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLITE; NONHUMAN; PARACRINE SIGNALING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; 1,25(OH)2D; ANIMAL; CARDIOVASCULAR SYSTEM; DIET SUPPLEMENTATION; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

1,25(OH)2D; CARDIOVASCULAR DISEASE; VITAMIN D;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIETARY SUPPLEMENTS; HUMANS; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84897109759     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.301241     Document Type: Review

References (169)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
2. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MD, Manson JE, Murad M, Kovacs CS. The nonskeletal effects of vitamin D: An Endocrine Society Scientific statement. Endocr Rev. 2011;33:456-492.
3. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest. 1987;79:1706-1712.
4. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int J Epidemiol. 1981;10:337-341.
5. Motiwala SR, Wang TJ. Vitamin D and cardiovascular risk. Curr Hypertens Rep. 2012;14:209-218.
6. Richart T, Li Y, Staessen JA. Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension. Am J Hypertens. 2007;20:1007-1015.
7. Brouwer-Brolsma EM, Bischoff-Ferrari HA, Bouillon R, et al. Vitamin D: Do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe. Osteoporos Int. 2013;24:1567-1577.
8. Battault S, Whiting SJ, Peltier SL, Sadrin S, Gerber G, Maixent JM. Vitamin D metabolism, functions and needs: from science to health claims. Eur J Nutr. 2013;52:429-441.
9. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
10. Dawson-Hughes B. Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women. Am J Clin Nutr. 2004;80:1763S-1766S.
11. Institute of Medicine of the National Academies. http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D. aspx. Accessed March 7, 2013.
12. Lai JK, Lucas RM, Banks E, Ponsonby AL; Ausimmune Investigator Group. Variability in vitamin D assays impairs clinical assessment of vitamin D status. Intern Med J. 2012;42:43-50.
13. Razzaque MS. The dualistic role of vitamin D in vascular calcifications. Kidney Int. 2011;79:708-714.
14. Nagy L, Szanto A, Szatmari I, Széles L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev. 2012;92:739-789.
15. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338:143-156.
16. Jorde R, Schirmer H, Wilsgaard T, Joakimsen RM, Mathiesen EB, Njølstad I, Løchen ML, Figenschau Y, Berg JP, Svartberg J, Grimnes G. Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study. PLoS One. 2012;7:e37295.
17. Dastani Z, Li R, Richards B. Genetic regulation of vitamin D levels. Calcif Tissue Int. 2013;92:106-117.
18. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-Torres J; IOF Committee of Scientific Advisors (CSA) Nutrition Working Group. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807-1820.
19. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008;102:1540-1544.
20. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726-776.
21. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;111:1666-1671.
22. Merke J, Milde P, Lewicka S, Hügel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E. Identification and regulation of 1, 25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1, 25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest. 1989;83:1903-1915.
23. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology. 2008;149:558-564.
24. Guillot X, Semerano L, Saidenberg-Kermanac'h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint Bone Spine. 2010;77:552-557.
25. Silvagno F, De Vivo E, Attanasio A, Gallo V, Mazzucco G, Pescarmona G. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLoS One. 2010;5:e8670.
26. Norman AW. Vitamin D receptor: new assignments for an already busy receptor. Endocrinology. 2006;147:5542-5548.
27. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science. 1999;283:1317-1321.
28. Karlic H, Varga F. Impact of vitamin D metabolism on clinical epigenics. Clin Epigenet. 2011;2:55-61.
29. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha, 25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol. 2004;18:2660-2671.
30. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, Goleva E. Vitamin D inhibitsmonocyte/macrophage proinflammatory cytokine production. J Immunol. 2012;188:2127-35.
31. Jones G. Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs. Annu Rev Nutr. 2013;33:23-44.
32. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation- linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011;57:63-69.
33. Mill C, George SJ. Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res. 2012;95:233-240.
34. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2008;295:H289-H296.
35. Dong J, Wong SL, Lau CW, Lee HK, Ng CF, Zhang L, Yao X, Chen ZY, Vanhoutte PM, Huang Y. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J. 2012;33:2980-2990.
36. Chen S, Law CS, Gardner DG. Vitamin D-dependent suppression of endothelin- induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J Steroid Biochem Mol Biol. 2010;118:135-141.
37. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1, 25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13:621-629.
38. Mitsuhashi T, Morris RC Jr, Ives HE. 1, 25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87:1889-1895.
39. Rebsamen MC, Sun J, Norman AW, Liao JK. 1alpha, 25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res. 2002;91:17-24.
40. Molinari C, Uberti F, Grossini E, Vacca G, Carda S, Invernizzi M, Cisari C. 1α, 25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell Physiol Biochem. 2011;27:661-668.
41. Bukoski RD, DeWan P, McCarron DA. 1, 25 (OH)2 vitamin D3 modifies growth and contractile function of vascular smooth muscle of spontaneously hypertensive rats. Am J Hypertens. 1989;2:553-556.
42. Lamawansa MD, Wysocki SJ, House AK, Norman PE. Vitamin D3 exacerbates intimal hyperplasia in balloon-injured arteries. Br J Surg. 1996;83:1101-1103.
43. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis. 2006;186:20-28.
44. Shalhoub V, Shatzen E, Henley C, Boedigheimer M, McNinch J, Manoukian R, Damore M, Fitzpatrick D, Haas K, Twomey B, Kiaei P, Ward S, Lacey DL, Martin D. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int. 2006;79:431-442.
45. Jono S, Nishizawa Y, Shioi A, Morii H. 1, 25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98:1302-1306.
46. Schmidt N, Brandsch C, Kühne H, Thiele A, Hirche F, Stangl GI. Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. PLoS One. 2012;7:e35316.
47. Pierce RA, Kolodziej ME, Parks WC. 1, 25-Dihydroxyvitamin D3 represses tropoelastin expression by a posttranscriptional mechanism. J Biol Chem. 1992;267:11593-11599.
48. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res. 2007;44:11-18.
49. Wu Y, Craig TA, Lutz WH, Kumar R. Identification of 1 alpha, 25-dihydroxyvitamin D3 response elements in the human transforming growth factor beta 2 gene. Biochemistry. 1999;38:2654-2660.
50. Cardus A, Panizo S, Encinas M, Dolcet X, Gallego C, Aldea M, Fernandez E, Valdivielso JM. 1, 25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis. 2009;204:85-89.
51. Chen Y, Liu W, Sun T, Huang Y, Wang Y, Deb DK, Yoon D, Kong J, Thadhani R, Li YC. 1, 25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J Immunol. 2013;190:3687-3695.
52. Helming L, Böse J, Ehrchen J, Schiebe S, Frahm T, Geffers R, Probst- Kepper M, Balling R, Lengeling A. 1alpha, 25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood. 2005;106:4351-4358.
53. Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford). 2010;49:1466-1471.
54. Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1Alpha, 25-dihydroxyvitamin D3 inhibits CD40L-induced pro- inflammatory and immunomodulatory activity in human monocytes. Cytokine. 2009;45:190-197.
55. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R. 1alpha, 25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation. 2000;102:2867-2872.
56. Riek AE, Oh J, Sprague JE, Timpson A, de las Fuentes L, Bernal- Mizrachi L, Schechtman KB, Bernal-Mizrachi C. Vitamin D suppression of endoplasmic reticulum stress promotes an antiatherogenic monocyte/macrophage phenotype in type 2 diabetic patients. J Biol Chem. 2012;287:38482-38494.
57. Szeto FL, Reardon CA, Yoon D, Wang Y, Wong KE, Chen Y, Kong J, Liu SQ, Thadhani R, Getz GS, Li YC. Vitamin D receptor signaling inhibits atherosclerosis in mice. Mol Endocrinol. 2012;26:1091-1101.
58. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB, Bernal-Mizrachi L, Bernal-Mizrachi C. 1, 25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009;120:687-698.
59. Takeda M, Yamashita T, Sasaki N, Nakajima K, Kita T, Shinohara M, Ishida T, Hirata K. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol. 2010;30:2495-2503.
60. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167:4974-4980.
61. Rahman A HS, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D knockout mice. J Steroid Biochem Mol Biol. 2007;103:416-419.
62. Pilz S, Tomaschitz A, Drechsler C, Dekker JM, März W. Vitamin D deficiency and myocardial diseases. Mol Nutr Food Res. 2010;54:1103-1113.
63. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288:E125-E132.
64. Chen S, Ni X-P, Humphreys MH, Gardner DG. 1, 25( OH)2-dihydroxyvitamin D amplifies type A natiuretic peptide expression and activity in target cells. J Am Soc Nephrol. 2005;16:329-339.
65. Yamamoto T, Kozawa O, Tanabe K, Akamatsu S, Matsuno H, Dohi S, Hirose H, Uematsu T. 1, 25-dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch Biochem Biophys. 2002;398:1-6.
66. Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011;124:1838-1847.
67. Li Q, Gardner DG. Negative regulation of the human atrial natriuretic peptide gene by 1, 25-dihydroxyvitamin D3. J Biol Chem. 1994;269:4934-4939.
68. Zhao G, Simpson RU. Interaction between vitamin D receptor with caveolin-3 and regulation by 1, 25-dihydroxyvitamin D3 in adult rat cardiomyocytes. J Steroid Biochem Mol Biol. 2010;121:159-163.
69. O'Connell TD, Simpson RU. 1, 25-Dihydroxyvitamin D3 regulation of myocardial growth and c-myc levels in the rat heart. Biochem Biophys Res Commun. 1995;213:59-65.
70. Lahoute C, Herbin O, Mallat Z, Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol. 2011;8:348-358.
71. O'Connell TD, Weishaar RE, Simpson RU. Regulation of myosin isozyme expression by vitamin D3 deficiency and 1, 25-dihydroxyvitamin D3 in the rat heart. Endocrinology. 1994;134:899-905.
72. Kyaw T, Winship A, Tay C, Kanellakis P, Hosseini H, Cao A, Li P, Tipping P, Bobik A, Toh BH. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE- deficient mice. Circulation. 2013;127:1028-1039.
73. Rose K, Penna-Martinez M, Klahold E, Kärger D, Shoghi F, Kahles H, Bayer M, Hintermann E, Pfeilschifter JM, Badenhoop K, Ramos-Lopez E, Christen U. Influence of the vitamin D plasma level and vitamin D-related genetic polymorphisms on the immune status of patients with type 1 diabetes: A pilot study. Clin Exp Immunol. 2013;171:171-185.
74. Frederiksen BN, Kroehl M, Fingerlin TE, Wong R, Steck AK, Rewers M, Norris JM. Association between vitamin D metabolism gene polymorphisms and risk of islet autoimmunity and progression to type 1 diabetes: The diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab. 2013;98:E1845-E1851.
75. Beilfuss J, Berg V, Sneve M, Jorde R, Kamycheva E. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine. 2012;60:870-874.
76. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol. 2012;109:226-230.
77. Hamzaoui K, Ben Dhifallah I, Karray E, Sassi FH, Hamzaoui A. Vitamin D modulates peripheral immunity in patients with Behçet's disease. Clin Exp Rheumatol. 2010;28:S50-S57.
78. Raymond MA, Désormeaux A, Labelle A, Soulez M, Soulez G, Langelier Y, Pshezhetsky AV, Hébert MJ. Endothelial stress induces the release of vitamin D-binding protein, a novel growth factor. Biochem Biophys Res Commun. 2005;338:1374-1382.
79. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, Toprak A, Yazici D, Sancak S, Deyneli O, Akalin S. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94:4023-4030.
80. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, Kavtaradze N, Uphoff I, Hooper C, Tangpricha V, Alexander RW, Brigham K, Quyyumi AA. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011;58:186-192.
81. Mayer O Jr, Filipovský J, Seidlerová J, Vanek J, Dolejšová M, Vrzalová J, Cífková R. The association between low 25-hydroxyvitamin D and increased aortic stiffness. J Hum Hypertens. 2012;26:650-655.
82. Giallauria F, Milaneschi Y, Tanaka T, Maggio M, Canepa M, Elango P, Vigorito C, Lakatta EG, Ferrucci L, Strait J. Arterial stiffness and vitamin D levels: The Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2012;97:3717-3723.
83. Karohl C, Vaccarino V, Veledar E, Goldberg J, Tangpricha V, Bellasi A, Raggi P. Vitamin D status and coronary flow reserve measured by positron emission tomography: A co-twin control study. J Clin Endocrinol Metab. 2013;98:389-397.
84. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, Li K, Bassali R, Guo DH, Thomas J, Pierce GL, White J, Holick MF, Zhu H. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25- hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab. 2010;95:4584-4591.
85. Breslavsky A, Frand J, Matas Z, Boaz M, Barnea Z, Shargorodsky M. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients. Clin Nutr. 2013;32:970-975.
86. Yiu YF, Chan YH, Yiu KH, Siu CW, Li SW, Wong LY, Lee SW, Tam S, Wong EW, Cheung BM, Tse HF. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:E830-E835.
87. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, Rashid G. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008;294:F1059-F1064.
88. Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of 1, 25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int. 1987;41:112-114.
89. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229-238.
90. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC. 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282:29821-29830.
91. Cheng Q, Li YC, Boucher BJ, Leung PS. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia. 2011;54:2077-2081.
92. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74:170-179.
93. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: A systematic review. Nat Rev Cardiol. 2009;6:621-630.
94. Vaidya A, Forman JP, Hopkins PN, Seely EW, Williams JS. 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst. 2011;12:311-319.
95. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159-1165.
96. Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25- hydroxyvitamin D concentration and hypertension: A meta-analysis. J Hypertens. 2011;29:636-645.
97. Waugh JM, Yuksel E, Li J, Kuo MD, Kattash M, Saxena R, Geske R, Thung SN, Shenaq SM, Woo SL. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res. 1999;84:84-92.
98. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279:35798-35802.
99. Stach K, Kälsch AI, Nguyen XD, Elmas E, Kralev S, Lang S, Weiss C, Borggrefe M, Kälsch T. 1α, 25-dihydroxyvitamin D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial cells. Cardiology. 2011;118:107-115.
100. Hyppönen E, Berry D, Cortina-Borja M, Power C. 25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: A cross sectional analysis in the 1958 British Birth Cohort. PLoS One. 2010;5:e10801.
101. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, Doria A, Cervera R, Miesbach W, Stojanovich L, Barak V, Porat-Katz BS, Amital H, Shoenfeld Y. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70:145-150.
102. Brøndum-Jacobsen P, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. 25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18, 791 participants. J Thromb Haemost. 2013;11:423-431.
103. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-1151.
104. Deng GG, Martin-McNulty B, Sukovich DA, Freay A, Halks-Miller M, Thinnes T, Loskutoff DJ, Carmeliet P, Dole WP, Wang YX. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res. 2003;92:510-517.
105. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe- Court D, Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787-796.
106. Wasse H, Cardarelli F, De Staercke C, Hooper C, Veledar E, Guessous I. 25-hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. BMC Nephrol. 2011;12:24.
107. Yao Z, Jaeger JC, Ruzzo WL, Morale CZ, Emond M, Francke U, Milewicz DM, Schwartz SM, Mulvihill ER. A Marfan syndrome gene expression phenotype in cultured skin fibroblasts. BMC Genomics. 2007;8:319.
108. Hinek A, Botney M, Mecham R, Parks W. Inhibition of tropoelastin expression by 1, 25-dihdroxyvitamin D3. Connect Tiss Res. 1991;26:155-166.
109. Bendeck MP, Langille BL. Rapid accumulation of elastin and collagen in the aortas of sheep in the immediate perinatal period. Circ Res. 1991;69:1165-1169.
110. Norman P, Moss I, Sian M, Gosling M, Powell J. Maternal and postnatal vitamin D ingestion influences rat aortic structure, function and elastin content. Cardiovasc Res. 2002;55:369-374.
111. van de Luijtgaarden KM, Voûte MT, Hoeks SE, Bakker EJ, Chonchol M, Stolke RJ, Rouwet EV, Verhagen HJ. Vitamin D deficiency may be an independent risk factor for arterial disease. Eur J Vas Endovasc Surg. 2012;44:301-306.
112. Wong YYE, Flicker L, B YB, A MK, Hankey GJ, Norman PE. Is hypovitaminosis D associated with abdominal aortic aneurysm, and is there a dose-response relationship? Eur J Vasc Endovasc Surg 2013; 45:657-664.
113. Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, Borretta G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 1999;50:321-328.
114. Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, Klingel K. Osteopontin: A fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res. 2009;104:851-859.
115. Santillán GE, Vazquez G, Boland RL. Activation of a beta- Adrenergic-sensitive signal transduction pathway by the secosteroid hormone 1, 25-(OH)2-vitamin D3 in chick heart. J Mol Cell Cardiol. 1999;31:1095-1104.
116. Kosecik M, Ertas T. Dilated cardiomyopathy due to nutritional vitamin D deficiency rickets. Pediatr Int. 2007;49:397-399.
117. Agarwal M, Phan A, Willix R Jr, Barber M, Schwarz ER. Is vitamin D deficiency associated with heart failure? A review of current evidence. J Cardiovasc Pharmacol Ther. 2011;16:354-363.
118. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo- controlled trial. Am J Clin Nutr. 2006;83:754-759.
119. Witham MD, Crighton LJ, Gillespie ND. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: A randomised controlled trial. Circ Heart Fail. 2010;3:195-201.
120. Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski MK, Silljé HH, van Gilst WH, Jaarsma T, de Boer RA. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail. 2011;13:619-625.
121. Towler DA, Demer LL. Thematic series on the pathobiology of vascular calcification. Circ Res. 2011;108:1378-1380.
122. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755-1760.
123. Zebger-Gong H, Müller D, Diercke M, Haffner D, Hocher B, Verberckmoes S, Schmidt S, D'Haese PC, Querfeld U. 1, 25-Dihydroxyvitamin D3- induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix. J Hypertens. 2011;29:339-348.
124. Niederhoffer N, Bobryshev YV, Lartaud-Idjouadiene I, Giummelly P, Atkinson J. Aortic calcification produced by vitamin D3 plus nicotine. J Vasc Res. 1997;34:386-398.
125. Rodriguez M, Martinez-Moreno JM, Rodríguez-Ortiz ME, Muñoz- Castañeda JR, Almaden Y. Vitamin D and vascular calcification in chronic kidney disease. Kidney Blood Press Res. 2011;34:261-268.
126. Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res. 2006;21:484-490.
127. Tintut Y, Patel J, Territo M, Saini T, Parhami F, Demer LL. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105:650-655.
128. Li X, Speer MY, Yang H, Bergen J, Giachelli CM. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol. 2010;30:321-326.
129. Cozzolino M, Bruschetta E, Stucchi A, Ronco C, Cusi D. Role of vitamin D receptor activators in cardio-renal syndromes. Semin Nephrol. 2012;32:63-69.
130. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008;19:1509-1519.
131. Moe SM. Klotho: A master regulator of cardiovascular disease? Circulation. 2012;125:2181-2183.
132. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22:124-136.
133. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012;125:2243-2255.
134. Wu-Wong JR, Noonan W, Ma J, Dixon D, Nakane M, Bolin AL, Koch KA, Postl S, Morgan SJ, Reinhart GA. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther. 2006;318:90-98.
135. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205:255-260.
136. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503-511.
137. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50:303-312.
138. Ponda MP, Huang X, Odeh MA, Breslow JL, Kaufman HW. Vitamin D may not improve lipid levels: A serial clinical laboratory data study. Circulation. 2012;126:270-277.
139. Wang H, Xia N, Yang Y, Peng DQ. Influence of vitamin D supplementation on plasma lipid profiles: A meta-analysis of randomized controlled trials. Lipids Health Dis. 2012;11:42.
140. Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, Perkins BA, Harris SB, Zinman B, Hanley AJ. Association of vitaminD with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care. 2010;33:1379-1381.
141. Pittas AG, Sun Q, Manson JE, Dawson-Hughes B, Hu FB. Plasma 25- hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care. 2010;33:2021-2023.
142. Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P; IMDIAB Group. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: The IMDIAB XIII trial. Diabetes Care. 2010;33:1962-1963.
143. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: A systematic review. Eur J Clin Nutr. 2011;65:1005-1015.
144. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men. Arch Int Med. 2008;168:1174-1180.
145. Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. 25- hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta- Analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol. 2012;32: 2794-2802.
146. Brøndum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25- hydroxyvitamin D and symptomatic ischemic stroke: An original study and meta-analysis. Ann Neurol. 2013;73:38-47.
147. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-1637.
148. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57:1595-1603.
149. Skaaby T, Husemoen LL, Pisinger C, Jørgensen T, Thuesen BH, Fenger M, Linneberg A. Vitamin D status and cause-specific mortality: A general population study. PLoS One. 2012;7:e52423.
150. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency and mortality risk in the general population: A meta-analysis of prospective cohort studies. Am J Clin Nutr. 2012;95:91-100.
151. Schöttker B, Haug U, Schomburg L, Köhrle J, Perna L, Müller H, Holleczek B, Brenner H. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr. 2013;97:782-793.
152. Semba RD, Houston DK, Bandinelli S, Sun K, Cherubini A, Cappola AR, Guralnik JM, Ferrucci L. Relationship of 25-hydroxyvitamin D with allcause and cardiovascular disease mortality in older community- dwelling adults. Eur J Clin Nutr. 2010;64:203-209.
153. Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso HD. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5:819-829.
154. Melamed ML, Muntner P, Michos ED, Uribarri J, Weber C, Sharma J, Raggi P. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol. 2008;28:1179-1185.
155. Gouveri E, Papanas N, Hatzitolios AI, Maltezos E. Hypovitaminosis D and peripheral arterial disease: emerging link beyond cardiovascular risk factors. Eur J Intern Med. 2012;23:674-681.
156. Ogren M, Hedblad B, Engström G, Janzon L. Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study 'Men born in 1914' from Malmö, Sweden. Eur J Vasc Endovasc Surg. 2005;29:182-189.
157. Hyde Z, Mylankal KJ, Hankey GJ, Flicker L, Norman PE. Peripheral arterial disease increases the risk of subsequent hip fracture in older men: The Health in Men Study. Osteoporos Int. 2013;24:1683-1688.
158. Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol. 2008;19:1239-1246.
159. Sanders KM, Nicholson GC, Ebeling PR. Is high dose vitamin D harmful? Calcif Tissue Int. 2013;92:191-206.
160. Robinson-Cohen C, Hoofnagle AN, Ix JH, Sachs MC, Tracy RP, Siscovick DS, Kestenbaum BR, de Boer IH. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA. 2013;310:179-188.
161. Freedman BI, Register TC. Effect of race and genetics on vitamin D metabolism, bone and vascular health. Nat Rev Nephrol. 2012;8:459-466.
162. McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease. Ann Int Med. 2011;155:820-826.
163. Jääskeläinen T, Knekt P, Marniemi J, Sares-Jäske L, Männistö S, Heliövaara M, Järvinen R. Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health. Eur J Nutr. 2013;52:513-525.
164. Levin GP, Robinson-Cohen C, de Boer IH, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012;308:1898-1905.
165. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, Erwin PJ, Hensrud DD, Murad MH, Montori VM. Vitamin D and cardiovascular outcomes: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:1931-1942.
166. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33:159-171.
167. Vidal M, Ramana CV, Dusso AS. Stat1-vitamin D receptor interactions antagonize 1, 25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol. 2002;22:2777-2787.
168. Picotto G, Liaudat AC, Bohl L, Tolosa de Talamoni N. Molecular aspects of vitamin D anticancer activity. Cancer Invest. 2012;30:604-614.
169. Lundberg AM, Hansson GK. Innate immune signals in atherosclerosis. Clin Immunol. 2010;134:5-24.